Posted by Michael Wonder on 19 May 2020
Bevespi Aerosphere approved in China for patients with COPD
18 May 2020 - First approval in China of a fixed-dose, long-acting dual bronchodilator in a pressurised metered-dose inhaler device.
AstraZeneca’s Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in China as a maintenance treatment to relieve symptoms in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.
